Results 261 to 270 of about 206,398 (317)

Sympathectomy in refractory ventricular arrhythmias in patients with left ventricular assist device: a grand round case report. [PDF]

Eur Heart J Case Rep
Fernández-Caso M, Carta-Bergaz A, Castrodeza J, Sousa-Casasnovas I, Ortiz-Bautista C, Pedraz-Prieto Á, Barrio-Gutiérrez JM, Bermejo J.   +7 more
europepmc   +1 more source

The Impact of Obesity on Durable Left Ventricular Assist Device Implantation: A Systematic Review and Meta‐Analysis

Artificial Organs, EarlyView.
14 100 LVAD patients across 21 studies were analyzed. Findings indicated that obese LVAD recipients had lower short‐term mortality and higher risk of infection, thrombosis and right heart failure. There was no difference in long‐term survival between obese and non‐obese patients.
Hugh Jacobs, Olivia Frost, Arian Arjomandi Rad, Wing Kiu Chou, Sadeq Al‐Saegh, Alina Zubarevich, Alexander Weymann, Arjang Ruhparwar, Lukman Amanov, Peyman Sardari Nia, Antonios Kourliouros, Thanos Athanasiou   +11 more
wiley   +1 more source

Subclinical myocardial dysfunction assessed by cardiac magnetic resonance feature tracking predicts ventricular arrhythmias in early-stage hypertension. [PDF]

Front Cardiovasc Med
Fang B, Liao W, Zhong J, Zhong J.
europepmc   +1 more source

Outcomes in Patients Requiring VENO‐Venous Extracorporeal Membrane Oxygenation After Cardiac Surgery: An Analysis From the PELS‐1 Study

Artificial Organs, EarlyView.
We report an insight from the PELS‐1– a multicentre, international registry focusing on postocardiotomy extracorporeal support use between 2000 and 2020. We focused on 24/2163 (1.1%) patients requiring V‐V ECMO after cardiac surgery. Mortality was high, with 21.7% of patients discharged alive and an overall 1‐year survival probability of 12.5 ...
Pasquale Nardelli, Silvia Mariani, Maria Elena De Piero, Bas C. T. van Bussel, Michele Di Mauro, Ann‐Kristin Schaefer, Diyar Saeed, Matteo Pozzi, Luca Botta, Udo Boeken, Robertas Samalavicius, Karl Bounader, Xiaotong Hou, Jeroen J. H. Bunge, Hergen Buscher, Leonardo Salazar, Bart Meyns, Michael A. Mazzeffi, Marco L. Sacha Matteucci, Sandro Sponga, Kollengode Ramanathan, Claudio Russo, Francesco Formica, Pranya Sakiyalak, Antonio Fiore, Daniele Camboni, Giuseppe Maria Raffa, Rodrigo Diaz, I‐wen Wang, Jae‐Seung Jung, Jan Belohlavek, Vin Pellegrino, Giacomo Bianchi, Matteo Pettinari, Alessandro Barbone, José P. Garcia, Kiran Shekar, Glenn Whitman, Roberto Lorusso, PELS Investigators   +39 more
wiley   +1 more source

Population‐Based Study Found Low Risk of Misdiagnosing Long QT Syndrome as Breath‐Holding Spells in Swedish Children

Acta Paediatrica, EarlyView.
ABSTRACT Aim An electrocardiogram is commonly recommended in breath‐holding spell management, mainly to rule out long QT syndrome. This retrospective study investigated the risk of long QT syndrome being misdiagnosed as breath‐holding spells in a paediatric population in southern Sweden.
Sanna Hellström Schmidt, Ida Jeremiasen, Erik A. Eklund, Cornelis Jan Pronk   +3 more
wiley   +1 more source

Case Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse. [PDF]

Front Physiol
Alzammam A, Alanazi F, Alenazy S, Alsalman A, Albadi A, Almegbel M, Aljizeeri A, Altaweel M, Almusaad A.   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure. [PDF]

Ann Noninvasive Electrocardiol
Arzhangzadeh A, Nikoo MH, Haghjoo M, Rasekh F, Shojaei S, Mousavi A, Nozhat S, Narimani-Javid R, Bazroodi H, Neisi S, Mojibpour M, Abedini M, Eslamzadeh S, Drissi HB, Shafiei S.   +14 more
europepmc   +1 more source